Romain Najman

This inventor holds 31 USPTO granted patents and 8 published patent applications, plus 13 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Abivax, Institut Curie, Universitè De Montpellier. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Romain Najman. Retrieved from https://idiyas.com/inventor/romain-najman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 13 (Patent Applications = 6)

EPO Patents = 20 (Patent Applications = 31)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 151(Granted Patents)

Location History:

L'Hay-les-Roses, FR (2015 - 2023)
L'Hay-les'Roses, FR (2024)

Company Filing History:

Universitè De Montpellier

patents

4. 30 out of 5,383

Centre National De La Recherche Scientifique

patents

5. 1 out of 132

Centre National De La Recherche Scientifique

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Quinoline Derivatives

RNA Virus Treatment

Cancer Compounds

Inflammatory Diseases

Therapeutic Agents

miRNA Biomarkers

P53 Expression

Retrovirus Treatment

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617756 - Substituted imidazolidines for treating a RNA virus infection (2026-05-05),

2. 12479802 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2025-11-25),

3. 12421206 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-09-23),

4. 12247018 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-03-11),

5. 12084422 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2024-09-10),

6. 11739073 - Aryl-n-aryl derivatives for treating a RNA virus infection (2023-08-29),

7. 11649211 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

8. 11649210 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

9. 11441181 - miRNA-124 as a biomarker (2022-09-13),

10. 11427566 - Compounds useful for treating cancer (2022-08-30),

11. 11014918 - Compounds and pharmaceutical compositions containing at least one of the compounds (2021-05-25),

12. 10981874 - Use of quinoline derivatives for the treatment of inflammatory diseases (2021-04-20),

13. 10975063 - Compound, and production method thereof, and methods of treatment using the compound (2021-04-13),

14. 10806729 - Quinoline derivatives for use in the treatment or prevention of viral infection (2020-10-20),

15. 10718770 - Methods for screening compounds for treating or preventing a viral infection or a virus-related condition (2020-07-21),

Title: The Visionary Inventor: Romain Najman's Journey of Innovation

Introduction:

Romain Najman, a visionary inventor based in L'Hay-les-Roses, FR, is renowned for his relentless pursuit of excellence in the world of technology. With a remarkable portfolio of 26 patents, his passion for innovation continues to inspire the next generation of inventors and shape the future of technology.

Latest Patents:

Among his latest patents is the groundbreaking discovery of Aryl-n-aryl derivatives for treating RNA virus infections. This compound shows promise in the treatment and prevention of RNA virus infections caused by viruses belonging to group IV or V of the Baltimore classification. Additionally, Romain Najman's use of quinoline derivatives for the treatment of inflammatory diseases showcases his commitment to developing novel solutions for pressing healthcare challenges.

Career Highlights:

Throughout his illustrious career, Romain Najman has made significant contributions to the field of technology. Having worked in esteemed companies such as Abivax and Institut Curie, he has garnered a wealth of experience and expertise in driving innovation forward. His innovative spirit and dedication to pushing the boundaries of what is possible have earned him a reputation as a trailblazer in the industry.

Collaborations:

Romain Najman's collaborations with notable coworkers such as Jamal Tazi and Didier Scherrer have been instrumental in advancing his groundbreaking research. By working alongside talented individuals who share his passion for innovation, he has been able to bring his visionary ideas to life and make a lasting impact on the world of technology.

Conclusion:

In conclusion, Romain Najman's journey as a visionary inventor exemplifies the transformative power of innovation. Through his groundbreaking patents, illustrious career highlights, and fruitful collaborations, he continues to push the boundaries of technological advancement and inspire future generations of inventors to dream big and pursue excellence in their quest to shape a better tomorrow.

Profile summary based on public USPTO records.